The developer of a nasal spray-mist erectile dysfunction (ED) treatment, LTR Pharma (ASX:LTP) has revealed a new product – Roxus – to achieve early US sales ahead of eventual Food and Drug ...

The developer of a nasal spray-mist erectile dysfunction (ED) treatment, LTR Pharma (ASX:LTP) has revealed a new product – Roxus – to achieve early US sales ahead of eventual Food and Drug ...

Health Check: LTR Pharma finds fast-track path to US erectile dysfunction market The developer of a spray-based erectile dysfunctional treatment, LTR Pharma has found a pre-approval route to the ...

The developer of a nasal spray-mist erectile dysfunction (ED) treatment, LTR Pharma (ASX:LTP) has revealed a new product – Roxus – to achieve early US sales ahead of eventual Food and Drug ...

The developer of a nasal spray-mist erectile dysfunction (ED) treatment, LTR Pharma (ASX:LTP) has revealed a new product – Roxus – to achieve early US sales ahead of eventual Food and Drug ...

The developer of a spray-based erectile dysfunctional treatment, LTR Pharma has found a pre-approval route to the US market. As with LTR’s foundation product Spontan, Roxus is based on the ...

The developer of a spray-based erectile dysfunctional treatment, LTR Pharma has found a pre-approval route to the US market. As with LTR’s foundation product Spontan, Roxus is based on the ...

Health Check: LTR Pharma finds fast-track path to US erectile dysfunction market The developer of a spray-based erectile dysfunctional treatment, LTR Pharma has found a pre-approval route to the ...

The developer of a nasal spray-mist erectile dysfunction (ED) treatment, LTR Pharma (ASX:LTP) has revealed a new product – Roxus – to achieve early US sales ahead of eventual Food and Drug ...